MedTrace Logo

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

NCT00833781 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-03-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.

Conditions

  • HIV-1 Infection
  • HIV Infections

Interventions

BIOLOGICAL

mRNA-transfected autologous dendritic cells

Injections will be administered intradermally at weeks 0, 2, 6 and 10.

BIOLOGICAL

autologous dendritic cells with no mRNA transfection

Injections will be administered intradermally at weeks 0, 2, 6 and 10.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Rajesh Gandhi, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833781 on ClinicalTrials.gov